The present study examined the effects of transforming growth factor (TGF)-β3, connective tissue growth factor (CTGF) and tissue inhibitor of metalloproteinase 1 (TIMP1) gene transduction, using a lentiviral vector, on rabbit intervertebral disc degeneration in vivo, with the intention of investigating their potential use in gene therapy. The lenti‑TGFβ3‑P2A‑CTGF‑T2A‑TIMP1 was injected into degenerative lumbar intervertebral discs and the results indicated that the degeneration was ameliorated in the experimental group when compared with the control and the puncture group. Furthermore, the expression levels of type II collagen and aggreca is significantly higher in the experimental group. These results indicate the potential of gene therapy in treatment of intervertebral disc degeneration.
In this study, the authors design lentiviral vectors to overexpressed TGF-3 and in the same time silenced type I collagen. They transduced ynovium-derived mesenchymal stem cells for articular cartilage engineering and following characterizations are also described.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
The present study examined the effects of transforming growth factor (TGF)-β3, connective tissue growth factor (CTGF) and tissue inhibitor of metalloproteinase 1 (TIMP1) gene transduction, using a lentiviral vector, on rabbit intervertebral disc degeneration in vivo, with the intention of investigating their potential use in gene therapy. The lenti‑TGFβ3‑P2A‑CTGF‑T2A‑TIMP1 was injected into degenerative lumbar intervertebral discs and the results indicated that the degeneration was ameliorated in the experimental group when compared with the control and the puncture group. Furthermore, the expression levels of type II collagen and aggreca is significantly higher in the experimental group. These results indicate the potential of gene therapy in treatment of intervertebral disc degeneration.